(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Lego's $650 Pokémon set is already sold out as demand, preorders surge - 2How mountain terraces have helped Indigenous peoples live with climate uncertainty
- 3NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- 4Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- 5Manual for Savvy Home Lighting Framework: Lights up Your Space
- The Best Business visionaries Under 30
- Vote In favor of Feasible Way You Prescribe to Shop for Garments
- China's Normal Ponders: A Visual Excursion
- 6 Well known Nissan Vehicles in the U.S.
- What is colostrum? And should you be taking it?
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- Investigating the World's Chief Authentic Urban communities to Visit
- Israel faces tough choices over haredi draft exemptions, legal expert warns
